Micron Biomedical, an Atlanta, GA-based life science firm growing a needle-free know-how for medication and vaccines that’s based mostly on dissolvable microarrays, raised $16m extending its Sequence A funding to over $33M.
The newest spherical was led by J2 Ventures and the World Well being Funding Company (GHIC).
The corporate intends to make use of the funds to broaden operations and its R&D sector.
Led by CEO Steve Damon, Micron Biomedical makes a speciality of dissolvable microarray-based, drug and vaccine administration know-how. Its proprietary dissolvable, microarray know-how know-how is designed to enhance entry and obtain higher well being outcomes globally by means of injection-free, painless, and easy and/or self-administration of medication and vaccines, and by eliminating or decreasing the necessity for chilly chain transport and storage, enhancing security and efficacy, and enhancing affected person compliance.
FinSMEs
16/01/2025
